Diamyd Medical AB (DMYDY.PK) said its third-quarter pre-tax loss narrowed to SEK 1.93 million from last year's SEK 43.61 million.
Loss reduced to SEK 1.93 million from SEK 43.45 million in the same quarter a year ago.
Group net sales amounted to SEK 348 thousand, significantly lower than SEK 19.53 million in the prior-year quarter.
Separately, Diamyd Medical revealed that a Phase II study evaluating the company's drug candidate NP2 Enkephalin did not meet its primary objective of reducing pain in subjects with severe intractable cancer pain. The treatment was however well tolerated, confirming the safety of the company's NTDDS technology.
The purpose of the randomized, double-blind, and placebo-controlled Phase II study is to evaluate the effect of intradermal injection of NP2 Enkephalin on pain reported by subjects suffering from severe intractable pain due to cancer, as well as to confirm the safety of the treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.